UTRS (Minerva Surgical) LT-Debt-to-Total-Asset: 0.43 (As of Sep. 2023)


What is Minerva Surgical LT-Debt-to-Total-Asset?

Minerva Surgical UTRS -99.00% LT-Debt-to-Total-Asset is 0.43 as of Sep. 2023.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Minerva Surgical's long-term debt to total assests ratio for the quarter that ended in Sep. 2023 was 0.43.

Minerva Surgical's long-term debt to total assets ratio declined from Sep. 2022 (0.47) to Sep. 2023 (0.43). It may suggest that Minerva Surgical is progressively becoming less dependent on debt to grow their business.

Minerva Surgical  (OTCPK:UTRS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Minerva Surgical LT-Debt-to-Total-Asset Related Terms

Minerva Surgical LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Minerva Surgical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minerva Surgical LT-Debt-to-Total-Asset Chart

Minerva Surgical Annual Data
Trend Dec19 Dec20 Dec21 Dec22
LT-Debt-to-Total-Asset
1.63 1.04 0.34 0.54

Minerva Surgical Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.54 0.40 0.44 0.43

Minerva Surgical LT-Debt-to-Total-Asset Calculation

Minerva Surgical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )/Total Assets (A: Dec. 2022 )
=37.441/68.9
=0.54

Minerva Surgical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (Q: Sep. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2023 )/Total Assets (Q: Sep. 2023 )
=31.279/72.785
=0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.43 mean?
Minerva Surgical (UTRS) has a LT-Debt-to-Total-Asset of 0.43 as of Sep. 2023. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Minerva Surgical and its competitors.
Is Minerva Surgical's LT-Debt-to-Total-Asset too high?
Minerva Surgical's current LT-Debt-to-Total-Asset is 0.43.
How does Minerva Surgical's LT-Debt-to-Total-Asset compare to PAVM and ELUT?
Minerva Surgical's LT-Debt-to-Total-Asset of 0.43 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Minerva Surgical and its competitors. Minerva Surgical's current LT-Debt-to-Total-Asset is 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minerva Surgical stock overvalued right now?
Minerva Surgical (UTRS) has a current LT-Debt-to-Total-Asset of 0.43. The current LT-Debt-to-Total-Asset is 0.43. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Minerva Surgical (UTRS), the current LT-Debt-to-Total-Asset is 0.43 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minerva Surgical Business Description

Address 4255 Burton Drive, Santa Clara, CA, USA, 95054
Minerva Surgical Inc is a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner. The Company operates and manages its business as one reportable and operating segment, which is the business of research, development, and sale of therapeutic devices for abnormal uterine bleeding treatment.